The virtronectin protein sequence and the parts of things such as igf-i (+ i think 4 others) are joined together into a single protein. There is AFAIK no resemblance between vitronection being a device that delivers active ingredient.
The single a large protein sites there where it is put. The extra bits stuck onto it prote cell migration across the vitrogro scafold. As the would goes through the early phases of healing
and the cells start to form a new layer of skin, then the vtirogro scaffold is ripped up by the growing skin, and effectively "dissolves" in kinda the same way dissolving suture s will.
WARNINGS: I am not even a biochemists backside and have no actual documentable expertise. DYOR. like really DYOR.
The above is provided as framework AS IS, so that you can then read other info into it and see if it checks out.
If anyone knows better or has contradictory facts, ta.
Id like to know.
FYI: When pottering around in the old ASX releases you are looking for the announcments where they originally scaled up manufacture. They were rather chuffed, for what looked like good reason, when one advance was made which meant the compound became one a large protein instead of 4-5 separate ones. At that time you may find IIRC, comments about the increased safety and ease of manufacture as an all in one winning improvement.
DYOR, like really DYOR on this.
TIS Price at posting:
29.5¢ Sentiment: Buy Disclosure: Held